近日，北京鞍石生物科技股份有限公司(下称“鞍石生物”或“公司”)科创板IPO获受理，成为又一家采用第五套上市标准冲刺 资本市场 的 创新药 企。在资本市场持续深化改革的背景下，鞍石生物采用的标准彰显了监管层对创新药企的包容与支持，更折射出我国 生物医药 产业从研发导向向商业化转型的重要趋势。行业赛道前景广阔，差异化竞争把握增长机遇从行业来看，中国MET-TKI药物市场具有广阔的发展前景。根据灼识...
Source Link近日，北京鞍石生物科技股份有限公司(下称“鞍石生物”或“公司”)科创板IPO获受理，成为又一家采用第五套上市标准冲刺 资本市场 的 创新药 企。在资本市场持续深化改革的背景下，鞍石生物采用的标准彰显了监管层对创新药企的包容与支持，更折射出我国 生物医药 产业从研发导向向商业化转型的重要趋势。行业赛道前景广阔，差异化竞争把握增长机遇从行业来看，中国MET-TKI药物市场具有广阔的发展前景。根据灼识...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.